Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692379 | 0.85 | PDE2A (0.30) | — | |
| SCHEMBL9518044 | 0.81 | SLC18A3 (0.44) | SLC18A3SIGMAR1CFTROPRL1 | |
| SCHEMBL6745262 | 0.81 | SLC18A3 (0.44) | SLC18A3SIGMAR1CFTROPRL1 | |
| SCHEMBL6744668 | 0.81 | SLC18A3 (0.44) | SLC18A3SIGMAR1CFTROPRL1 | |
| SCHEMBL1008634 | 0.81 | PDE2A (0.39) | — | |
| SCHEMBL31521292 | 0.81 | OPRL1 (0.38) | OPRL1 | |
| SCHEMBL28300325 | 0.76 | KDM4E (0.43) | — | |
| SCHEMBL1010807 | 0.75 | CES2 (0.39) | — | |
| SCHEMBL30692412 | 0.75 | PDE2A (0.34) | SLC18A3SIGMAR1 | |
| SCHEMBL30692418 | 0.71 | KDM1A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | SLC18A3 1069/4885SIGMAR1 4378/4885CFTR 3006/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | SLC18A3 1069/4885SIGMAR1 4378/4885CFTR 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.